abstract |
The invention refers to novel 2-(1,2,4-triazole-1-yl)-1,3,4-thiadiazole derivatives of formula (I) having an influence on the heart and the central nervous system, furthermore pharmaceutical compositions containing the above derivatives, and a process for the preparations of the novel compounds. In formula (I) R1 represents a hydrogen atom, a C1-4 alkyl group of a phenyl group optionally substituted by 1 to 3 substituents selected from the group defined in the application, Z stands for a hydrogen atom of a C1-4 alkoxy group, R0 means a group of the formula Alk-NR4R5 wherein Alk is a C1-6 straight of branched chain alkylene group, R4 and R5 represent, independently, a hydrogen atom, a C2-6 alkenyl group, a C1-8 alkyl group optionally substituted by a substituent selected from the group defined in the application or R4 and R5 form together with the adjacent nitrogen atom and optionally with one or more further nitrogen and/or oxygen and/or sulfur atom(s) a 5- to 10-membered saturated heterocyclic group, optionally substituted, one of R2 and R3 is an amino group, while the other stands for an amino group of a 5- to 10-membered saturated heterocyclic group containing one or more nitrogen and/or oxygen and/or sulfur atom(s) and being linked through its nitrogen atom, said heterocyclic group being optionally substituted or the latter one of R2 and R3 means a group of formula -SR wherein R represents a C1-8 alkyl group, a C2-6 alkenyl group or a C2-6 alkinyl group, wherein the alkyl group is optionally substituted by a phenyl group of a halophenyl group, and optionally one or both amino group(s) is/are substituted by 1 of 2 substituent(s) selected from the group consisting of a C1-6 alkyl group, a C2-6 alkenyl group, a phenyl(C1-4 alkyl) group or a halophenyl-(C1-4 alkyl) group. |